Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Hospital Incidence and Medical Costs of Female Breast Cancer in Spain: A Retrospective Multicenter Study

Author(s): Josep Darbà* and Alicia Marsà

Volume 18, Issue 4, 2022

Published on: 06 September, 2022

Page: [285 - 291] Pages: 7

DOI: 10.2174/1573394718666220511115125

Price: $65

Abstract

Background: Breast cancer is the most prevalent cancer in women worldwide, causing the greatest number of cancer-related deaths. This study aimed to evaluate the use of healthcare resources associated with female breast cancer in Spain, to analyze trends in hospitalization and death rates, and the related direct medical costs.

Methods: A retrospective multicenter study analyzed records of hospital and ambulatory visits of women diagnosed with breast cancer in Spanish hospitals between 1st January 2005 and 31st December 2018.

Results: In total, 353,080 admission files were reviewed, mainly inpatient hospital admissions, corresponding to 299,585 individual patients. The median patient age was 59 years, 12.7% of admissions registered the presence of metastatic tumors, and 15.7% registered unspecified secondary tumors. The mean in-hospital death rate was 3.0% for patients without a metastatic disease and 10.5% for patients with metastatic disease, decreasing significantly over the study period. The total ageadjusted hospitalization rate increased between 2005 and 2011 and decreased after 2012. The mean direct medical cost was €3824 per outpatient visit, €3995 per hospital admission up to 3 days and €5001 per hospital admission over 3 days. Admission costs increased in patients with metastatic disease and those deceased during hospitalization.

Conclusion: This study supports previous findings regarding the relative increase in breast cancer incidence that could be attributed to the intensive screening and the reduction in the death rate. Mean direct medical cost in this study varied greatly with the length of stay, presence of metastatic tumors and disease fatality.

Keywords: Breast cancer, mortality, incidence, healthcare cost, Spain, metastatic tumors.

« Previous Next »
Graphical Abstract

[1]
Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol 2019; 5(12): 1749-68.
[http://dx.doi.org/10.1001/jamaoncol.2019.2996] [PMID: 31560378]
[2]
Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España 2020 [Cancer figures in Spain 2020] 2020. Available from: https://seom.org/publicaciones/el-cancer-en-espanya.com (Accessed on: 23 Jul 2020)
[3]
Baeyens-Fernández JA, Molina-Portillo E, Pollán M, et al. Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study. BMC Cancer 2018; 18(1): 781.
[http://dx.doi.org/10.1186/s12885-018-4682-1] [PMID: 30068302]
[4]
Warrier S, Tapia G, Goltsman D, Beith J. An update in breast cancer screening and management. Womens Health (Lond Engl) 2016; 12(2): 229-39.
[http://dx.doi.org/10.2217/whe.15.105] [PMID: 26689336]
[5]
Castells X, Sala M, Ascunce N, et al. Description of cancer screenings in Spain; Project DESCRIC Informes de Evaluación de Tecnologías Sanitarias, AATRM 2006/01 2006. Available from: https://www.seepidemiologia.es/descargas/grupos_de_trabajo/InformeDESCRIC.pdf
[6]
Sociedad Española de Oncología Médica (SEOM). Manual SEOM de prevención y diagnóstico precoz del cáncer [SEOM guidelines for the prevention and early diagnosis of cancer] SEOM 2017. Available from: https://seom.org/publicaciones/publicaciones-seom/prevencion-y-diagnostico-precoz (Accessed on: 24 Jul 2020).
[7]
Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 2019; 1152: 51-64.
[http://dx.doi.org/10.1007/978-3-030-20301-6_4] [PMID: 31456179]
[8]
Clèries R, Martínez JM, Moreno V, Yasui Y, Ribes J, Borràs JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology 2013; 24(3): 454-60.
[http://dx.doi.org/10.1097/EDE.0b013e31828b0866] [PMID: 23493031]
[9]
Clèries R, Ameijide A, Buxó M, et al. Long-term crude probabilities of death among breast cancer patients by age and stage: A population-based survival study in Northeastern Spain (Girona-Tarragona 1985-2004). Clin Transl Oncol 2018; 20(10): 1252-60.
[http://dx.doi.org/10.1007/s12094-018-1852-1] [PMID: 29511947]
[10]
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol 2013; 14(12): 1165-74.
[http://dx.doi.org/10.1016/S1470-2045(13)70442-X] [PMID: 24131614]
[11]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[12]
Centers for disease control and prevention (CDC).. International classification of diseases, ninth revision, clinical modification (ICD-9-CM) 2015. Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm (Accessed on: 26 Jun 2020).
[13]
Centers for Disease Control and Prevention (CDC). International classification of diseases, tenth revision, clinical modification (ICD-10-CM) 2020. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm (Accessed on: 26 Jun 2020).
[14]
Law 14/2007, 3 July, on biomedical research (BOE, 4 July 2007). Rev Derecho Genoma Hum 2007; (26): 283-325.
[PMID: 18201045]
[15]
Pollán M. Epidemiology of breast cancer in young women. Breast Cancer Res Treat 2010; 123 (Suppl. 1): 3-6.
[http://dx.doi.org/10.1007/s10549-010-1098-2] [PMID: 20711654]
[16]
Jiménez Puente A, García-Alegría J, Lara-Blanquer A. Information systems for clinicians I. How to know what type of patients are attended in our hospitals. Rev Clin Esp 2010; 210(6): 298-303.
[http://dx.doi.org/10.1016/j.rce.2010.02.002] [PMID: 20447622]
[17]
Ng HS, Vitry A, Koczwara B, Roder D, McBride ML. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Cancer Causes Control 2019; 30(9): 931-41.
[http://dx.doi.org/10.1007/s10552-019-01203-0] [PMID: 31280456]
[18]
Garcia-Estevez L, Moreno-Bueno G. Updating the role of obesity and cholesterol in breast cancer. Breast Cancer Res 2019; 21(1): 35.
[http://dx.doi.org/10.1186/s13058-019-1124-1] [PMID: 30823902]
[19]
Rocco N, Montagna G, Di Micco R, et al. The impact of the COVID-19 pandemic on surgical management of breast cancer: Global trends and future perspectives. Oncologist 2021; 26(1): e66-77.
[http://dx.doi.org/10.1002/onco.13560] [PMID: 33044007]
[20]
Obispo B, Rogado J, Lara Álvarez MÁ. The other cost of the pandemic. Clin Breast Cancer 2022; 22(1): e108.
[http://dx.doi.org/10.1016/j.clbc.2021.05.001] [PMID: 34176733]
[21]
Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019; 321(3): 288-300.
[http://dx.doi.org/10.1001/jama.2018.19323] [PMID: 30667505]
[22]
Park J, Look KA. Health care expenditure burden of cancer care in the United States. Inquiry 2019; 56: 46958019880696.
[http://dx.doi.org/10.1177/0046958019880696] [PMID: 31583928]
[23]
Broekx S, Den Hond E, Torfs R, et al. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 2011; 12(4): 311-7.
[http://dx.doi.org/10.1007/s10198-010-0237-3] [PMID: 20306109]
[24]
Oliva-Moreno J, Peña-Longobardo LM. Labour productivity loss caused by premature deaths associated with breast cancer: Results from Spain over a 10-year period. Breast Cancer Res Treat 2018; 172(3): 571-6.
[http://dx.doi.org/10.1007/s10549-018-4963-z] [PMID: 30209732]
[25]
Arrospide A, Rue M, van Ravesteyn NT, et al. Economic evaluation of the breast cancer screening programme in the Basque Country: Ret-rospective cost-effectiveness and budget impact analysis. BMC Cancer 2016; 16: 344.
[http://dx.doi.org/10.1186/s12885-016-2386-y] [PMID: 27251556]
[26]
Arrospide A, Soto-Gordoa M, Acaiturri T, López-Vivanco G, Abecia LC, Mar J. Cost of breast cancer treatment by clinical stage in the Basque Country, Spain. Rev Esp Salud Pública 2015; 89(1): 93-7.
[http://dx.doi.org/10.4321/S1135-57272015000100010] [PMID: 25946589]
[27]
Nagini S. Breast cancer: Current molecular therapeutic targets and new players. Anticancer Agents Med Chem 2017; 17(2): 152-63.
[http://dx.doi.org/10.2174/1871520616666160502122724] [PMID: 27137076]
[28]
Ministry of Health. Consumer Affairs and Social Welfare Health Care Information and Statistics Ministry of Health, Consumer Affairs and Social Welfare 2019. Available from: https://www.mscbs.gob.es/estadEstudios/sanidadDatos/home.htm (Accessed on: 24 Jul 2020.)

Rights & Permissions Print Cite
Article Metrics
17
2
© 2024 Bentham Science Publishers | Privacy Policy